Hemostasis Today

July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Alejandro González Veliz: Key Takeaways from the 2026 ACC Scientific Statement on Antiplatelet Therapy
Jul 11, 2026, 08:37

Alejandro González Veliz: Key Takeaways from the 2026 ACC Scientific Statement on Antiplatelet Therapy

Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn about recent article by Dharam J. Kumbhani et al., published in JACC Journals, adding:

“Antiplatelet therapy has entered a new era.

The 2026 ACC Scientific Statement emphasizes that the optimal strategy is no longer defined by fixed durations or universal protocols, but by individualized assessment of ischemic and bleeding risks.

From aspirin in primary prevention to shortened DAPT, P2Y12 inhibitor monotherapy, and long-term secondary prevention, the focus has shifted toward precision medicine.

Understanding when to intensify and when to de-escalate treatment may have a greater impact on outcomes than choosing a specific drug.

Which recommendation do you think will have the greatest impact on your daily practice?

Share your thoughts below.

JACC 2026″

Title: Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology

Authors: Dharam J. Kumbhani, C. Michael Gibson, Scott Kinlay, Eric D. Peterson, Amy W. Pollak, Jacqueline E. Tamis-Holland, and Freek W.A. Verheugt

Alejandro González Veliz: Key Takeaways from the 2026 ACC Scientific Statement on Antiplatelet Therapy

Stay updated on all scientific advances with Hemostasis Today.